Oncodiagnosis Panel: 2002 - Adult Central Nervous System Neoplasms

Radiographics

Volumn 23, Issue 6, 2003, Pages 1591-1611

  Brown, Paul D ^a   Wald, John T ^a   McDermott, Mike W ^b   Baumann, Glen S ^c   Cloughesy, Tim F ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain neoplasms, 10.3634, 10.3635, 10.382, 144.366; Brain neoplasms, diagnosis, 10.3634, 10.3635, 10.382, 144.366; Brain neoplasms, therapeutic radiology, 10.3634, 10.3635, 10.382, 144.366; Brain neoplasms, therapy, 10.3634, 10.3635, 10.382, 144.366

Indexed keywords

ADULT; ADULTHOOD; BRAIN RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; MEDICAL SPECIALIST; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; POSTOPERATIVE PERIOD; QUESTIONNAIRE; RADIOSURGERY; SURGICAL APPROACH; TREATMENT PLANNING; TUMOR BIOPSY; ARTICLE; CASE REPORT; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC ERROR; FEMALE; GLIOMA; MENINGIOMA; MULTIPLE SCLEROSIS; OPTIC NERVE TUMOR; OPTIC NEURITIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BRAIN ABSCESS; BRAIN TUMOR; CRANIOTOMY; CYST; FATALITY; FRONTAL LOBE; GLIOBLASTOMA; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARIETAL LOBE; PATHOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; PALLIATIVE THERAPY; SALVAGE THERAPY; HEADACHE; OLIGODENDROGLIOMA; PHOTOPHOBIA; REOPERATION;

ADULT; DIAGNOSTIC ERRORS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; MENINGIOMA; MULTIPLE SCLEROSIS; OPTIC NERVE NEOPLASMS; OPTIC NEURITIS; RADIOTHERAPY, CONFORMAL; ANTINEOPLASTIC AGENTS; BRAIN ABSCESS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CRANIOTOMY; CYSTS; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; FRONTAL LOBE; GLIOBLASTOMA; MALE; MIDDLE AGED; PARIETAL LOBE; QUINAZOLINES; RADIOTHERAPY, ADJUVANT; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; PALLIATIVE CARE; RADIOSURGERY; SALVAGE THERAPY; DISEASE PROGRESSION; HEADACHE; OLIGODENDROGLIOMA; PHOTOPHOBIA; REOPERATION;

ANTINEOPLASTIC AGENT; GEFITINIB; QUINAZOLINE DERIVATIVE;

EID: 1542286707     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/rg.236035109     Document Type: Conference Paper

References (86)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002; 52:23-47. [Erratum: CA Cancer J Clin 2002; 52:119.]
2. Kolles H, Niedermayer I, Feiden W. Grading von astrozytomen und oligodendrogliomen. Pathologe 1998; 19:259-268.
3. Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys 1994; 28:405-413.
4. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 1992; 31:431-436.
5. Kaye AH, Walker DG. Low grade astrocytomas: controversies in management. J Clin Neurosci 2000; 7:475-483.
6. Janny P, Cure H, Mohr M, et al. Low grade supratentorial astrocytomas: management and prognostic factors. Cancer 1994; 73:1937-1945.
7. Morantz RA. Low-grade astrocytomas. In: Wilkins R, Rengachary SS, eds. Neurosurgery. New York, NY: McGraw-Hill, 1996; 789-798.
8. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994; 74:1784-1791.
9. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 1988; 38:1371-1374. [Erratum: Neurology 1988; 38:1816.]
10. Barker FG 2nd, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997; 80:936-941.
11. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neuro-oncol 1997; 34: 85-101.
12. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001; 95:735-745.
13. Szaflarski JP, Binder JR, Possing ET, McKiernan KA, Ward BD, Hammeke TA. Language lateralization in left-handed and ambidextrous people: fMRI data. Neurology 2002; 59:238-244.
14. Szymanski MD, Perry DW, Gage NM, et al. Magnetic source imaging of late evoked field responses to vowels: toward an assessment of hemispheric dominance for language. J Neurosurg 2001; 94: 445-453.
15. Skirboll SS, Ojemann GA, Berger MS, Lettich E, Winn HR. Functional cortex and subcortical white matter located within gliomas. Neurosurgery 1996; 38:678-684; discussion 684-685.
16. Black PM, Alexander E 3rd, Martin C, et al. Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. Neurosurgery 1999; 45:423-431; discussion 431-433.
17. Binder DK, Roberts H, Berger MS, Dillon W, McDermott MW. Impact of surgical navigation systems (SNS) on extent of resection (EOR) of glial tumors. Chicago, Ill: American Association of Neurological Surgeons, 2002.
18. Oser AB, Moran CJ, Kaufman BA, Park TS. Intracranial tumor in children: MR imaging findings within 24 hours of craniotomy. Radiology 1997; 205:807-812.
19. Dickman CA, Rekate HL, Bird CR, Drayer BP, Medina M. Unenhanced and gadolinium-DTPA-enhanced MR imaging in postoperative evaluation in pediatric brain tumors. J Neurosurg 1989; 71: 49-53. [Erratum: J Neurosurg 1989; 71(5 pt 1): 796.]
20. Hudgins PA, Davis PC, Hoffman JC Jr. Gadopentetate dimeglumine-enhanced MR imaging in children following surgery for brain tumor: spectrum of meningeal findings. AJNR Am J Neuroradiol 1991; 12:301-307.
21. Knauth M, Aras N, Wirtz CR, Dorfler A, Engelhorn T, Sartor K. Surgically induced intracranial contrast enhancement: potential source of diagnostic error in intraoperative MR imaging. AJNR Am J Neuroradiol 1999; 20:1547-1553.
22. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993; 78:909-914.
23. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992; 31:78-82.
24. Gururangan S, Cavazos CM, Ashley D, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 2002; 20:2951-2958.
25. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996; 46:203-207.
26. Soffietti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43: 1066-1073.
27. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 1992; 76:741-745.
28. Cairncross JG. Understanding low-grade glioma: a decade of progress. Neurology 2000; 54:1402-1403.
29. Henderson KH, Shaw EG. Randomized trials of radiation therapy in adult low-grade gliomas. Semin Radiat Oncol 2001; 11:145-151.
30. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997; 15:1294-1301.
31. Karim AB, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4 - an interim analysis. Int J Radiat Oncol Biol Phys 2002; 52:316-324.
32. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20:2267-2276.
33. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-2084.
34. Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999; 45:923-929.
35. Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas: a new pattern of prognostic factors. Cancer 1997; 79:370-379.
36. Jackson A, Kassner A, Annesley-Williams D, Reid H, Zhu XP, Li KL. Abnormalities in the recirculation phase of contrast agent bolus passage in cerebral gliomas: comparison with relative blood volume and tumor grade. AJNR Am J Neuroradiol 2002; 23:7-14.
37. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001; 22:604-612.
38. McKnight TR, von dem Bussche MH, Vigneron DB, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97:794-802.
39. Schultheiss TE, Kun LE, Ang KK, Stephens LC. Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995; 31:1093-1112. [Erratum: Int J Radiat Oncol Biol Phys 1995; 32: 1269.]
40. Morris DE, Bourland JD, Rosenman JG, Shaw EG. Three-dimensional conformal radiation treatment planning and delivery for low-and intermediate-grade gliomas. Semin Radiat Oncol 2001; 11:124-137.
41. Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 2002; 53:1254-1264.
42. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36:549-556.
43. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844) - EORTC Radiotherapy Co-operative Group. Eur J Cancer 1998; 34:1902-1909.
44. Kim DG, Kim CY, Paek SH, et al. Whole-body 18F FDG PET in the management of metastatic brain tumours. Acta Neurochir (Wien) 1998; 140: 665-673; discussion 673-674.
45. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721.
46. Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44:371-381.
47. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
48. Bindal AK, Bindal RK, Hess KR, et al. Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 1996; 84:748-754.
49. Lang FF, Sawaya R. Surgical management of cerebral metastases. Neurosurg Clin N Am 1996; 7:459-484.
50. Lang FF, Sawaya R. Surgical treatment of metastatic brain tumors. Semin Surg Oncol 1998; 14: 53-63.
51. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489.
52. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745-751.
53. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999; 45:427-434.
54. Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001; 51:426-434.
55. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53:519-526.
56. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of Radiation Therapy Oncology Group protocol (90-05). Int J Radiat Oncol Biol Phys 1996; 34:647-654.
57. Chan JH, Tsui EY, Chau LF, et al. Discrimination of an infected brain tumor from a cerebral abscess by combined MR perfusion and diffusion imaging. Comput Med Imaging Graph 2002; 26: 19-23.
58. Chang SC, Lai PH, Chen WL, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging 2002; 26:227-236.
59. Nakaiso M, Uno M, Harada M, Kageji T, Takimoto O, Nagahiro S. Brain abscess and glioblastoma identified by combined proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging: two case reports. Neurol Med Chir (Tokyo) 2002; 42:346-348.
60. Yingling CD, Ojemann S, Dodson B, Harrington MJ, Berger MS. Identification of motor pathways during tumor surgery facilitated by multichannel electromyographic recording. J Neurosurg 1999; 91:922-927.
61. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323-1329.
62. Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L. A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 1979; 51: 526-532.
63. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001; 92:420-433.
64. Prados MD, Wara WM, Sneed PK, et al. Phase III trial of accelerated hyperfractionation with or without difluoromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 49:71-77.
65. Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000; 6:3878-3884.
66. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71:2585-2597.
67. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999; 17:3389-3395.
68. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
69. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003; 13:52-61.
70. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68:22-29.
71. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5:1725-1731.
72. Gonzalez DG, Menten J, Bosch DA, et al. Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study. Radiother Oncol 1994; 32:98-105.
73. Scott CB, Curran WJ Jr, Scarantino C, et al. Long term results of RTOG 9006: a randomized trial of hyperfractionated radiotherapy to 72.0 Gy & carmustine vs standard RT & carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma patients - Proceedings of the American Society of Clinical Oncology (ASCO) (abstr). J Clin Oncol 1998; 17:1546.
74. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998; 41: 1005-1011.
75. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20:1635-1642.
76. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999; 91:251-260.
77. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
78. Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999; 43:79-88.
79. Bauman GS, Fisher BJ, Cairncross JG, Macdonald D. Bihemispheric malignant glioma: one size does not fit all. J Neuro-oncol 1998; 38:83-89.
80. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994; 29:835-839.
81. McDermott MW, Durity FA, Rootman J, Woodhurst WB. Combined frontotemporal-orbitozygomatic approach for tumors of the sphenoid wing and orbit. Neurosurgery 1990; 26:107-116.
82. Andrews DW, Faroozan R, Yang BP, et al. Fractionated stereotactic radiotherapy for the treatment of optic nerve sheath meningiomas: preliminary observations of 33 optic nerves in 30 patients with historical comparison to observation with or without prior surgery. Neurosurgery 2002; 51: 890-902; discussion 903-904.
83. Turbin RE, Thompson CR, Kennerdell JS, Cockerham KP, Kupersmith MJ. A long-term visual outcome comparison in patients with optic nerve sheath meningioma managed with observation, surgery, radiotherapy, or surgery and radiotherapy. Ophthalmology 2002; 109:890-899; discussion 899-900.
84. Debus J, Wuendrich M, Pirzkall A, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 2001; 19:3547-3553.
85. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30:755-763.
86. Eng TY, Albright NW, Kuwahara G, et al. Precision radiation therapy for optic nerve sheath meningiomas. Int J Radiat Oncol Biol Phys 1992; 22:1093-1098.